

(use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number

Filing Date

First Named Inventor

David WALLACH

Group Art Unit

1644

Examiner Name

Attorney Docket Number

WALLACH=10D

100

01632929

78/04/03

[illegible][illegible]Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Pittenger 5/29/07

Substitute for form 1449A/PTO		Compleat if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	David WALLACH
		Group Art Unit	1644
		Examiner Name	
Sheet 2	of 4	Attorney Docket Number	WALLACH=10C

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AL	BALAVOINE et al, "Prostaglandin E ₂ and Collagenase Production by Fibroblasts and Synovial Cells Is Regulated by Urine-Derived Human Interleukin 1 and Inhibitor(s)", <u>J Clin Invest</u> 78:1120-1124 (1986)	
	AM	BEUTLER et al, "Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin", <u>Science</u> 229:869-871 (1985)	
	AN	BEUTLER et al, "Cachectin: More than a Tumor Necrosis Factor", <u>New Eng J Med</u> 316(7):379-385 (1987)	
	AO	BEUTLER et al, <u>Tumor Necrosis Factors ...</u> , Raven Press, New York, pp. 145, 383 (1992)	
	AP	BIGDA et al, "Dual Role of the p75 Tumor Necrosis Factor (TNF) Receptor in TNF Cytotoxicity", <u>J Exp Med</u> 180:445-460 (1994)	
	AQ	BROCKHAUS et al, "Monoclonal Antibodies against the TNF-Receptor Inhibit ...", 2 nd Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 140	
	AR	BROCKHAUS et al, "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies", <u>Proc Natl Acad Sci U S A</u> 87(8):3127-3131 (1990)	
	AS	CHEN et al, "Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors", <u>J Biol Chem</u> 270(6):2874-2878 (1995) (Abstract)	
	AT	CREASEY et al, "Biological Effects of Recombinant Human Tumor Necrosis Factor and Its Novel Muteins on Tumor and Normal Cell Lines", <u>Cancer Research</u> 47:145-149 (1987)	
	AU	ENGELMANN et al, "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine", <u>J Biol Chem</u> 265(3):1531-1536 (1990)	
	AV	HARRIS et al, "Therapeutic antibodies - the coming of age", <u>TIBTECH</u> 11:42-44 (1993)	
	AW	HIGUCHI et al, "Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies", <u>J Biol Chem</u> 267(29):20892-20899 (1992)	

Examiner Signature	Date Considered
--------------------	-----------------

Theresa G. Gage 5/29/07

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/APTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	
				Filing Date	
				First Named Inventor	David WALLACH
				Group Art Unit	1644
				Examiner Name	
Sheet 3	of 4	Attorney Docket Number	WALLACH=10C		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AX	HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", <u>J Biol Chem</u> 264(25):14927-14934 (1989)	
	AY	HOHMANN et al, "Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)", 2 nd Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan 15-20, 1989, p. 143	
	AZ	LOETSCHER et al, "Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells", <u>J Biol Chem</u> 265(33):20131-20138 (1990)	
	BA	NATANSON et al, "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis", <u>Annals of Int Med</u> 120(9):771-783 (1994)	
	BB	PARRILLO JE, "Pathogenetic Mechanisms of Septic Shock", <u>New Eng J Med</u> 328(20):1471-1477 (1993)	
	BC	PEETRE et al, "A tumor necrosis factor binding protein is present in human biological fluids", <u>Eur J Haematol</u> 41:414-419 (1988)	
	BD	SCHALL et al, "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor", <u>Cell</u> 61:361-370 (1990)	
	BE	SECKINGER et al, "A Human Inhibitor of Tumor Necrosis Factor alpha", <u>J Exp Med</u> 167:1511-1516 (1988)	
	BF	SMITH et al, "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", <u>Science</u> 248:1019-1023 (1990)	
	BG	STAUBER et al, "Human Tumor Necrosis Factor-alpha Receptor", <u>J Biol Chem</u> 263(35):19098-19104 (1986)	
	BH	TRACEY et al, "Shock and Tissue Injury Induced by Recombinant Human Cachectin", <u>Science</u> 234:470-474 (1986)	
	BI	TRACEY et al, "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia" <u>Nature</u> 330:662-664 (1987)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Philip G. Gaudin 5/29/07

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	David WALLACH
		Group Art Unit	1644
		Examiner Name	
Sheet 4	of 4	Attorney Docket Number	WALLACH=10C

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BJ	UNGLAUB et al, "Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators", <u>J Exp Med</u> 166:1788-1797 (1987)	
	BK	WALLACH D, "Cytotoxins (Tumor Necrosis Factor, Lymphotoxin and Others); Molecular Functional Characteristics and interactions with interferons", <u>Interferon</u> 7:90-124 (1986)	
	BL	WEIR (Ed.), <u>Handbook of Experimental Immunology</u> , Vol. 1, Blackwell Scientific Publications; Oxford, pp. 8.14-8.15	
	BM	WHITLOW et al, "Single-Chain Fv Proteins and Their Fusion Proteins", <u>Methods</u> 2(2):97-105 (1991)	



Examiner Signature	Date Considered
--------------------	-----------------

Patricia M. Jones 5/24/07

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10632929
	Filing Date		2003-08-04
	First Named Inventor	David WALLACH	
	Art Unit	1644	
	Examiner Name	P. Gambel	
	Attorney Docket Number	WALLACH10D	

	1	ENGELMANN, H., et al., "Antibodies to a Soluble Form of a Tumor Necrosis Factor (TNF) Receptor Have TNF-like Activity", Journal of Biological Chemistry, 265:14497-1504 (1990)	<input type="checkbox"/>
	2	ESPEVIK, T., et al., "Characterization of Binding and Biological Effects of Monoclonal Antibodies Against a Human Tumor Necrosis Factor Receptor", J. Exp. Med., 171:415-426 (1990)	<input type="checkbox"/>
If you wish to add additional non-patent literature document citation information please click the Add button			
EXAMINER SIGNATURE			
Examiner Signature		Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
<small> ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. </small>			

P. Gambel
5/24/07



BN/SB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/632,929
Filing Date	August 4, 2003
First Named Inventor	David WALLACH et al
Group Art Unit	1644
Examiner Name	Phillip Gambel
Attorney Docket Number	WALLACH=10D

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴	Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
BN		BANNER et al, "Crystal Structure of the Soluble Human 55 kd TNF Receptor-human TNF Beta Complex: Implications for TNF Receptor Activation", <u>Cell</u> 73(3):431-451 (1993)		
BO		JAATTELA M, "Biologic Activities and Mechanisms of Action of Tumor Necrosis Factor-alpha/cachectin", <u>Lab Invest</u> 64(6):724-742 (1991)		
BP		MARSTERS et al, "Identification of Cystein-rich Domains of the Type 1 Tumor Necrosis Factor Receptor Involved in Ligand Binding", <u>J Biol Chem</u> 267(9):5747-5750 (1992)		
BQ		ROTHER et al, "Tumor Necrosis Factor Receptors-structure and Function", <u>Immunol Res</u> 11(2):81-90 (1992)		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 15 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.